These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 4419369)

  • 1. Proceedings: Effects of piribedil (ET 495)--a dopaminergic receptor stimulating agent in Parkinson's disease.
    Lieberman A; Le Brun Y; Zolfaghari M
    Psychopharmacol Bull; 1974 Jul; 10(3):42-3. PubMed ID: 4419369
    [No Abstract]   [Full Text] [Related]  

  • 2. The use of dopaminergic receptor stimulating agent (Pribedil, ET 495) in Parkinson's disease.
    Lieberman A; Le Brun Y; Boal D; Zolfaghari M
    Adv Biochem Psychopharmacol; 1974; 12(0):415-25. PubMed ID: 4425258
    [No Abstract]   [Full Text] [Related]  

  • 3. Proceedings: Clinical studies of dopaminergic mechanisms.
    Chase TN
    Psychopharmacol Bull; 1974 Jul; 10(3):43-4. PubMed ID: 4419336
    [No Abstract]   [Full Text] [Related]  

  • 4. Clinical and pharmacological evaluation of the effects of piribedil in patients with parkinsonism.
    McLellan DL; Chalmers RJ; Johnson RH
    Acta Neurol Scand; 1975 Jan; 51(1):74-82. PubMed ID: 1091122
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Piribedil, a dopamine agonist, in Parkinson's disease.
    Sweet RD; Wasterlain CG; McDowell FH
    Clin Pharmacol Ther; 1974 Dec; 16(6):1077-82. PubMed ID: 4611465
    [No Abstract]   [Full Text] [Related]  

  • 6. Higher-dose glutathione therapy for Parkinson's disease in Japan: is it really safe?
    Naito Y; Matsuo K; Kokubo Y; Narita Y; Tomimoto H
    Mov Disord; 2010 May; 25(7):962; author reply 962-3. PubMed ID: 20131395
    [No Abstract]   [Full Text] [Related]  

  • 7. [Drugs and indications for medical treatment in Parkinson's disease (author's transl)].
    Allain H; Van den Driessche J; Menault F; Pape D; Reymann JM; Bentue-Ferrer D
    Sem Hop; 1980 Feb 8-15; 56(5-6):277-82. PubMed ID: 6243802
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Delusional infestation induced by piribedil add-on in Parkinson's disease.
    Kölle M; Lepping P; Kassubek J; Schönfeldt-Lecuona C; Freudenmann RW
    Pharmacopsychiatry; 2010 Aug; 43(6):240-2. PubMed ID: 20614418
    [No Abstract]   [Full Text] [Related]  

  • 9. Efficacy of piribedil as early combination to levodopa in patients with stable Parkinson's disease: a 6-month, randomized, placebo-controlled study.
    Ziegler M; Castro-Caldas A; Del Signore S; Rascol O
    Mov Disord; 2003 Apr; 18(4):418-25. PubMed ID: 12671949
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of CB1 cannabinoid receptor modulating compounds on the hyperkinesia induced by high-dose levodopa in the reserpine-treated rat model of Parkinson's disease.
    Segovia G; Mora F; Crossman AR; Brotchie JM
    Mov Disord; 2003 Feb; 18(2):138-49. PubMed ID: 12539206
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [A drug holiday in the treatment of Parkinson's disease].
    van Manen J
    Ned Tijdschr Geneeskd; 1986 May; 130(20):899-902. PubMed ID: 3724863
    [No Abstract]   [Full Text] [Related]  

  • 12. Treatment of drug-induced psychosis in Parkinson's disease with ziprasidone can induce severe dose-dependent off-periods and pathological laughing.
    Schindehütte J; Trenkwalder C
    Clin Neurol Neurosurg; 2007 Feb; 109(2):188-91. PubMed ID: 16949733
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Drugs for Parkinson's disease.
    Treat Guidel Med Lett; 2007 Oct; 5(62):89-94. PubMed ID: 17873854
    [No Abstract]   [Full Text] [Related]  

  • 14. Treatment of Parkinson's disease.
    Calne DB
    N Engl J Med; 1993 Sep; 329(14):1021-7. PubMed ID: 8366903
    [No Abstract]   [Full Text] [Related]  

  • 15. Parenteral ziprasidone: a new atypical neuroleptic for emergency treatment of psychosis in Parkinson's disease?
    Oechsner M; Korchounov A
    Hum Psychopharmacol; 2005 Apr; 20(3):203-5. PubMed ID: 15799011
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of ciladopa on Parkinson's disease: a preliminary report.
    Weiner WJ; Berger JR
    Adv Neurol; 1987; 45():583-6. PubMed ID: 3548268
    [No Abstract]   [Full Text] [Related]  

  • 17. [Pharmacological therapy of complicated Parkinson's disease].
    Jiménez-Jiménez FJ; Molina JA
    Rev Neurol; 1997 Aug; 25 Suppl 2():S170-9. PubMed ID: 9280685
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The effectiveness and tolerance of piribedil as adjunct therapy to levodopa in patients with Parkinson's disease: a nine month follow up].
    Salazar Tortolero G; Wix Ramos R; Salazar Aladrén P; Jiménez León JC
    Rev Neurol; 2004 Apr 16-30; 38(8):715-9. PubMed ID: 15122540
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pathological gambling in two patients on dopamine replacement therapy for Parkinson's disease.
    Avanzi M; Uber E; Bonfà F
    Neurol Sci; 2004 Jun; 25(2):98-101. PubMed ID: 15221629
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Drug treatment of Parkinson's disease.
    Callaghan N
    Ir Med J; 1983 Aug; 76(8):364-6. PubMed ID: 6618850
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.